Coherus Oncology (CHRS) Net Cash Flow Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) Net Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.47% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | 36.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.73% |
| Dec 31, 2025 | 59.83% |
| Sep 30, 2025 | -129.14% |
| Jun 30, 2025 | 67.26% |
| Mar 31, 2025 | 21.91% |
| Dec 31, 2024 | -20.66% |
| Sep 30, 2024 | -58.80% |
| Jun 30, 2024 | -50.83% |
| Mar 31, 2024 | 36.74% |
| Dec 31, 2023 | -55.02% |
| Sep 30, 2023 | -52.33% |
| Jun 30, 2023 | 21.87% |
| Mar 31, 2023 | -71.03% |
| Dec 31, 2022 | -168.59% |
| Sep 30, 2022 | -42.11% |
| Jun 30, 2022 | -59.38% |
| Mar 31, 2022 | -127.96% |
| Dec 31, 2021 | 58.14% |
| Sep 30, 2021 | 45.26% |
| Jun 30, 2021 | 13.73% |